GGI
TSHA icon

GordonMD Global Investments’s Taysha Gene Therapies TSHA Stock Holding History

GordonMD Global Investments’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Sell
723,185
-14,365
-2% -$85K 11.86% 3
2026
Q1 		$22.2M Sell
737,550
-593,351
-45% -$2.76M 15.47% 2
2025
Q4 		$7.32M Buy
+1,330,901
New +$6.46M 5.25% 7

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GordonMD Global Investments's TSHA Position: Q2 2026 in Review

GordonMD Global Investments reduced its Taysha Gene Therapies (TSHA) stake by 1.9% in Q2 2026, selling an estimated $85K and leaving 723,185 shares worth $24.5M. The position accounts for 11.86% of the portfolio, ranked #3.

GordonMD Global Investments first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • GordonMD Global Investments held 723,185 shares of Taysha Gene Therapies worth $24.5M as of Q2 2026.
  • GordonMD Global Investments sold 14,365 Taysha Gene Therapies shares in Q2 2026, an estimated $85K.
  • Taysha Gene Therapies made up 11.86% of GordonMD Global Investments's portfolio in Q2 2026, its #3 holding.
  • GordonMD Global Investments first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on GordonMD Global Investments's 13F filing for Q2 2026, filed 14 Aug 2026.